William Blair upgraded ARS Pharmaceuticals to Outperform from Market Perform after the company announced favorable top-line results from the repeat dosing study of neffy under nasal allergen conditions, addressing the concerns cited in the FDA’s CRL issued in 2023 and setting the company up for a resubmission in the second quarter and potential approval decision in the second half of 2024. Given the positive results and increased visibility into resubmission and launch timing, the firm is upgrading shares, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SPRY:
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
- ARS Pharmaceuticals to present efficacy data for neffy at 2024 AAAAI meeting
- ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting